Trillions of microorganisms that live on our bodies and inside the body - affect a number of threats to human health, including cancer, diabetes, heart disease and obesity. We can't pass by indifferently seeing the potential to of microbiome-based therapeutics.
Elucidating the biochemical mechanisms underlying this human supraorganism symbiosis is yielding new therapeutic insights to improve human health, treat disease, and potentially modify human disease risk factors.
It may be possible to prevent or treat abnormalities of the gut microbiota using modified organisms engineered through genetic or synthetic biology approaches.
We have a drive for rapid translation of our research into regulated, safe and efficacious therapies for patients which can be launched to the market and effectively change the way we treat disease.
We would love to meet up in person to discuss all the microbiome opportunities we have.
Passio Human Microbiome, founded in 2016, turns today’s microbiome science into tomorrow’s healthcare solutions. We lead broad microbiome research across a range of therapeutic areas. We are the only microbiome company developing microbiome therapeutic for Gestational Diabetes Mellitus, GDM.
Microbiome consists trillions of bacteria which colonise the human gut. It is crucial in shaping the host immune system & metabolism. The microbiome has 100x as many genes as the human genome and almost 95% of our microbiota is located in the GI tract. What’s interesting, the gut microbiota can weight up to 2 kg and the human body has more microbes than there are stars in the milky way. Moreover, each person has a unique gut microbiota, as individual as a fingerprint and about 90% of disease can be linked in some way back to the gut and health of the microbiome.
Our scientists combine science, translational medicine, and use powerful fields such as genomics, epigenomics, transcriptomics, proteomics, metabolomics and microfiometry, as well as bioinformatics to answer important questions about the microbiome. The aim is to use our strengths and the emerging possibilities of expanding the scope of research related to the microbiome. Our goal is to accelerate the development of microbial-based therapies.